Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
tryfon.zarganis-tzitzikas@cmd.ox.ac.uk

Research groups

The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI)

Tryfon Zarganis-Tzitzikas

Head of Chemistry, Alzheimer’s Research UK Oxford Drug Discovery Institute

Recent publications

Ugi-Tetrazole-Derived α-Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV-2 3CLpro

van der Straat R. et al, (2026), ACS MEDICINAL CHEMISTRY LETTERS

A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014-present).

Aiken SG. et al, (2025), Expert Opin Ther Pat, 35, 611 - 621

Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor.

O'Brien DP. et al, (2025), J Proteome Res, 24, 479 - 490

Covalent Inhibitors of S100A4 Block the Formation of a Pro-Metastasis Non-Muscle Myosin 2A Complex.

Giroud C. et al, (2024), J Med Chem, 67, 18943 - 18956

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors.

Ważyńska MA. et al, (2023), J Med Chem, 66, 9577 - 9591

More publications